MET and neoplasm: These analyses found lower survival in prostate cancer patients harbouring tumours with deep deletions in the met cycle genes (Supplementary Fig. 12a), and higher survival in kidney cancer patients where the met cycle enzymes are overexpressed (Supplementary Fig. 12b).